Circio's circVec tech shows 40-fold gene delivery improvement

Circio Holding ASA announced comprehensive in vivo data for its AAV-circVec 3.2 technology, showing a 40-fold improvement in protein expression in heart tissue compared to conventional mRNA-based AAV gene delivery. These statistically significant results were confirmed through both longitudinal live imaging and ex vivo tissue analyses. Similar promising results are observed in ongoing experiments targeting other tissues and AAV variants, supporting the broad applicability of the circVec platform.

The company has selected Danon disease as the initial cardiac indication to therapeutically validate the AAV-circVec technology. Chief technology officer Dr. Thomas B. Hansen highlighted that the latest circVec 3.2 generation incorporates a novel genetic feature driving superior AAV protein expression. Further enhanced circVec 4.0 is now entering initial in vivo screening. Chief executive Dr. Erik O. Wiklund noted the technology's potential for substantial dose reduction, which could improve safety, lower treatment costs, and transform the commercial viability of AAV therapy.